Posted by Michael Wonder on 19 Jul 2021
Aquestive Therapeutics announces FDA acceptance of new drug application resubmission for Libervant (diazepam) buccal film
19 July 2021 - Prescription Drug User Fee Act target goal date set for 23 December 2021.
Aquestive Therapeutics announced today that the U.S. FDA has accepted for filing the resubmission of the new drug application for Libervant (diazepam) buccal film for the management of seizure clusters.
